Outcome of fetuses with increased nuchal translucency

Current Opinion in Obstetrics and Gynecology

Volumn 13, Issue 2, 2001, Pages 169-174

  Bilardo, Caterina Maddalena ^a,b   Müller, Moira Annabel ^a   Pajkrt, Eva ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Department of Obstetrics and Gynaecology H4 205 ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CONGENITAL HEART MALFORMATION; DOWN SYNDROME; ECHOCARDIOGRAPHY; FETUS; FETUS ECHOGRAPHY; FETUS WASTAGE; HUMAN; MATERNAL AGE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ABNORMALITIES; CHROMOSOME ABERRATIONS; CHROMOSOME DISORDERS; FEMALE; FETAL DISEASES; HEART DEFECTS, CONGENITAL; HUMANS; NECK; PREGNANCY; PREGNANCY OUTCOME; PROGNOSIS; SENSITIVITY AND SPECIFICITY; ULTRASONOGRAPHY, PRENATAL;

EID: 0034922945     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200104000-00012     Document Type: Review

References (58)

1. The value of sonography in early pregnancy for the detection of fetal abnormalities in an unselected population
2. Increased first trimester nuchal translucency: Pregnancy and infant outcomes after routine screening for Down's syndrome in an unselected antenatal population
3. First trimester nuchal translucency: Effective routine screening for Down's syndrome
4. Screening for fetal aneuploidies and fetal cardiac abnormalities by nuchal translucency thickness measurement at 10-14 weeks of gestation as part of routine antenatal care in an unselected population
5. Effects of study design on the association between nuchal translucency measurement and Down syndrome
6. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation
7. Sonographic features of fetal trisomy 18 at 13 and 14 weeks: Four case reports
8. Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation
9. Increased nuchal translucency in trisomy 13 fetuses at 10-14 weeks of gestation
10. Screening for triploidy by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation
11. Lymphatic vessel hypoplasia in fetuses with Turner syndrome
12. Fetal 'space-suit' hydrops in the first trimester: Differentiating risk for chromosome abnormalities by delineating characteristics of nuchal translucency
13. Trisomy 10: First-trimester features on ultrasound, fetoscopy and postmortem of a case associated with increased nuchal translucency
14. Fetal loss in Down syndrome pregnancies
15. Maternal age- and gestation-specific risk for trisomy 21
16. Early pregnancy screening for fetal aneuploidy with serum markers and nuchal translucency
17. Nuchal thickness, urine beta-core fragment level, and maternal age for down syndrome screening
18. Efficiency of ultrasound and biochemical markers for Down's syndrome risk screening. A prospective study
19. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A
20. First-trimester nuchal translucency and maternal serum biochemical screening for Down's syndrome: A happy union?
21. First-trimester screening for Down syndrome using nuchal translucency measurement with free beta-hCG and PAPP-A between 10 and 13 weeks of pregnancy - The combined test
22. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters
23. Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency thickness at 10-14 weeks of gestation
24. Outcome of fetuses with enlarged nuchal translucency and normal karyotype
25. Pathophysiology of increased nuchal translucency in chromosomally abnormal fetuses
26. Prenatal sonographic diagnosis of Cantrell's pentalogy with cystic hygroma in the first trimester
27. A case of achondrogenesis type II associated with huge cystic hygroma: Prenatal diagnosis by ultrasonography
28. Caudal regression syndrome detected in a fetus with increased nuchal translucency
29. In-utero diagnosis of mucopolysaccharidosis type VII in a fetus with an enlarged nuchal translucency
30. Enlarged nuchal translucency and low serum protein concentrations as possible markers for Zellweger syndrome
31. First trimester nuchal anomalies as a prenatal sign of Zellweger syndrome
32. The association of increased fetal nuchal translucency and spinal muscular atrophy type I
33. Prenatal features of Noonan syndrome
34. Noonan syndrome: A cryptic condition in early gestation
35. Nuchal translucency in fetuses affected by homozygous alpha-thalassemia-1 at 12-13 weeks of gestation
36. Pregnancy outcome and nuchal translucency measurements in fetuses with a normal karyotype
37. Nuchal translucency measurement and pregnancy outcome in karyotypically normal fetuses
38. Increased fetal nuchal translucency thickness at 10-14 weeks: Is screening for maternal-fetal infection necessary?
39. Parvoviral infection associated with increased nuchal translucency: A case report
40. Screening for trisomy 21 in twin pregnancies by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation
41. Early prediction of severe twin-to-twin transfusion syndrome
42. Prenatal screening of congenital heart disease between ethics and cost-effectiveness. Time for a change in current prenatal ultrasound screening policies?
43. Current and potential impact of fetal diagnosis on prevalence and spectrum of serious congenital heart disease at term in the UK
44. Prenatal detection of heart defects at the routine fetal examination at 18 weeks in a non-selected population
45. Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: Population based cohort study
46. Incidence of congenital heart defects in fetuses of diabetic mothers: A retrospective study of 326 cases
47. Familial recurrence of congenital heart disease in a prospective series of mothers referred for fetal echocardiography
48. A possible increase in the incidence of congenital heart defects among the offspring of affected parents
49. Maternal drugs and congenital heart disease
50. Early diagnosis of major cardiac defects in chromosomally normal fetuses with increased nuchal translucency
51. First-trimester transabdominal fetal echocardiography
52. Limitations of using first trimester nuchal translucency measurement in routine screening for major congenital heart defects
53. What is fetal nuchal translucency?
54. Down's syndrome, cardiac anomalies, and nuchal translucency
55. Nuchal translucency and congenital heart defects: Heart failure or not?
56. Prenatal diagnosis of ventriculo-coronary fistula in a late first-trimester fetus presenting with increased nuchal translucency
57. Cardiac defects in chromosomally normal fetuses with abnormal ductus venosus blood flow at 10-14 weeks
58. Nuchal translucency, ductus venosus and congenital heart disease: An important association - A cautious analysis